Get started
SOPHiA GENETICS SASOPHiA GENETICS SASOPHiA GENETICS SA

SOPHiA GENETICS SA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SOPH chart


Full chart

SOPH upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪213.12 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.09 USD
Net income (FY)
‪−78.98 M‬ USD
Revenue (FY)
‪62.37 M‬ USD
Shares float
‪51.15 M‬
Beta (1Y)
0.33

Employees


Employees (FY)
449
Change (1Y)
−17 −3.65%
Revenue / Employee (1Y)
‪138.91 K‬ USD
Net income / Employee (1Y)
‪−175.90 K‬ USD

About SOPHiA GENETICS SA


Sector
Technology Services
Industry
Packaged Software
CEO
Jurgi Camblong
Website
sophiagenetics.com
Headquarters
Rolle
Founded
2011
ISIN
CH1125843347
FIGI
BBG011PFK7Q9
SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SOPH news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SOPH is 3.26 USD — it has increased by 5.16% in the past 24 hours. Watch SOPHiA GENETICS SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange SOPHiA GENETICS SA stocks are traded under the ticker SOPH.
SOPH stock has fallen by −0.31% compared to the previous week, the month change is a 1.24% rise, over the last year SOPHiA GENETICS SA has showed a −25.91% decrease.
We've gathered analysts' opinions on SOPHiA GENETICS SA future price: according to them, SOPH price has a max estimate of 11.00 USD and a min estimate of 5.00 USD. Watch SOPH chart and read a more detailed SOPHiA GENETICS SA stock forecast: see what analysts think of SOPHiA GENETICS SA and suggest that you do with its stocks.
SOPH reached its all-time high on Sep 1, 2021 with the price of 19.80 USD, and its all-time low was 1.69 USD and was reached on Nov 9, 2022. View more price dynamics on SOPH chart.
See other stocks reaching their highest and lowest prices.
SOPH stock is 6.65% volatile and has beta coefficient of 0.33. Track SOPHiA GENETICS SA stock price on the chart and check out the list of the most volatile stocks — is SOPHiA GENETICS SA there?
Yes, you can track SOPHiA GENETICS SA financials in yearly and quarterly reports right on TradingView.
SOPHiA GENETICS SA is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
SOPH earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.22 USD resulting in a −26.13% surprise. The estimated earnings for the next quarter are −0.21 USD per share. See more details about SOPHiA GENETICS SA earnings.
SOPHiA GENETICS SA revenue for the last quarter amounts to ‪15.85 M‬ USD, despite the estimated figure of ‪15.86 M‬ USD. In the next quarter, revenue is expected to reach ‪17.87 M‬ USD.
SOPH net income for the last quarter is ‪−18.44 M‬ USD, while the quarter before that showed ‪−15.19 M‬ USD of net income which accounts for −21.36% change. Track more SOPHiA GENETICS SA financial stats to get the full picture.
No, SOPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 449.00 employees. See our rating of the largest employees — is SOPHiA GENETICS SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOPHiA GENETICS SA EBITDA is ‪−60.00 M‬ USD, and current EBITDA margin is −109.94%. See more stats in SOPHiA GENETICS SA financial statements.
Like other stocks, SOPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOPHiA GENETICS SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SOPHiA GENETICS SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SOPHiA GENETICS SA stock shows the sell signal. See more of SOPHiA GENETICS SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.